Spots Global Cancer Trial Database for Depletion of Myeloid Derived Suppressor Cells to Enhance Anti PD-1 Therapy

Study Description

Brief Summary: Metastatic non small cell lung cancer can be treated with cytotoxic chemotherapy or using recently approved immunotherapy with antibody, Nivolumab. Both the therapies have limitation due to development of tolerance or immunosuppression. This trial combines one drug from each category, immunotherapeutic Nivolumab and chemotherapeutic gemcitabine as it was reported that gemcitabine reduces immunosuppression by killing myeloid derived suppressor cells, thereby increasing the efficacy of Nivolumab.

Detailed Description: Primary Objective • The primary objective of this proposal is to evaluate gemcitabine as a method of MDSC depletion. Secondary Objectives * Evaluate whether these measures result in enhanced T-cell activity and/or NK cell function and number. * Determine the tolerability and clinical activity (including response rate and survival) of this approach. * Correlate MDSC number with tumor PD-L1 expression

Keywords

Eligibility

Minimum Age: 18 Years

Eligible Ages: ADULT, OLDER_ADULT

Sex: ALL

Healthy Volunteers: No

Locations

Contact Details

Useful links and downloads for this trial